Sandbox Reserved 1170: Difference between revisions
From Proteopedia
Jump to navigationJump to search
Whitney Hart (talk | contribs) No edit summary |
No edit summary |
||
| Line 27: | Line 27: | ||
== Clinical Relevance == | == Clinical Relevance == | ||
By signaling predominantly through G<sub>aq/11</sub>, GPR40 increases intracellular calcium and activates phospholipases to generate diacylglycerols resulting in increased insulin secretion. Synthetic small-molecule agonists of GPR40 enhance insulin secretion in a glucose dependent manner in vitro and in vivo with a mechanism similar to that found with fatty acids. GPR40 agonists have shown efficacy in increasing insulin secretion and lowering blood glucose in rodent models of type 2 diabetes.<ref name="Burant"/> | By signaling predominantly through G<sub>aq/11</sub>, GPR40 increases intracellular calcium and activates phospholipases to generate diacylglycerols resulting in increased insulin secretion. Synthetic small-molecule agonists of GPR40 enhance insulin secretion in a glucose dependent manner [http://www.merriam-webster.com/medical/in%20vitro in vitro] and [http://www.merriam-webster.com/medical/in%20vivo in vivo] with a mechanism similar to that found with fatty acids. GPR40 agonists have shown efficacy in increasing insulin secretion and lowering blood glucose in rodent models of type 2 diabetes.<ref name="Burant"/> | ||
=== TAK-875 === | === TAK-875 === | ||
